IC
CRVS icon

Ikarian Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Ikarian Capital’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-338,100
Closed -$1.08M – 151
2025
Q1 		$1.08M Sell
338,100
-416,300
-55% -$1.96M 0.13% 96
2024
Q4 		$4.04M Buy
754,400
+536,100
+246% +$4M 0.55% 54
2024
Q3 		$1.15M Buy
+218,300
New +$784K 0.16% 92

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's CRVS Position: Q2 2022 in Review

Ikarian Capital sold out of Corvus Pharmaceuticals (CRVS) in Q2 2022, closing a stake of 510,126 shares — an estimated $837K sold.

Ikarian Capital first reported a position in CRVS in Q1 2021 and held it in 5 quarters. The position peaked at $3.67M in Q3 2021. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2022.

  • Ikarian Capital reported no remaining Corvus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 510,126 Corvus Pharmaceuticals shares in Q2 2022, an estimated $837K.
  • Ikarian Capital first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Ikarian Capital's Corvus Pharmaceuticals position peaked at $3.67M in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.